Cargando…

Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease

Recent studies have demonstrated that miR-34a expression is significantly upregulated and associated with apoptosis in nonalcoholic fatty liver disease (NAFLD). Carnosic acid (CA) is a novel antioxidant and a potential inhibitor of apoptosis in organ injury, including liver injury. This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Shan, W, Gao, L, Zeng, W, Hu, Y, Wang, G, Li, M, Zhou, J, Ma, X, Tian, X, Yao, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650741/
https://www.ncbi.nlm.nih.gov/pubmed/26203862
http://dx.doi.org/10.1038/cddis.2015.196
_version_ 1782401549773832192
author Shan, W
Gao, L
Zeng, W
Hu, Y
Wang, G
Li, M
Zhou, J
Ma, X
Tian, X
Yao, J
author_facet Shan, W
Gao, L
Zeng, W
Hu, Y
Wang, G
Li, M
Zhou, J
Ma, X
Tian, X
Yao, J
author_sort Shan, W
collection PubMed
description Recent studies have demonstrated that miR-34a expression is significantly upregulated and associated with apoptosis in nonalcoholic fatty liver disease (NAFLD). Carnosic acid (CA) is a novel antioxidant and a potential inhibitor of apoptosis in organ injury, including liver injury. This study aimed to investigate the signaling mechanisms underlying miR-34a expression and the antiapoptotic effect of CA in NAFLD. CA treatment significantly reduced the high-fat diet (HFD)-induced elevations in aminotransferase activity as well as in serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and malondialdehyde (MDA) levels but increased serum high-density lipoprotein cholesterol (HDL-C) and hepatic superoxide dismutase (SOD) levels. Moreover, CA treatment ameliorated the increase in cleaved caspase-3 caused by HFD exposure and completely reversed the HFD-induced decreases in manganese superoxide dismutase (MnSOD) and B-cell lymphoma-extra large expression. CA also counteracted the HFD- or palmitic acid (PA)-induced increases in caspase-3 and caspase-9 activity. Mechanistically, CA reversed the HFD- or PA-induced upregulation of miR-34a, which is the best-characterized regulator of SIRT1. Importantly, the decrease in miR-34a expression was closely associated with the activation of the SIRT1/p66shc pathway, which attenuates hepatocyte apoptosis in liver ischemia/reperfusion injury. A dual luciferase assay in L02 cells validated the modulation of SIRT1 by CA, which occurs at least partly via miR-34a. In addition, miR-34a overexpression was significantly counteracted by CA, which prevented the miR-34a-dependent repression of the SIRT1/p66shc pathway and apoptosis. Collectively, our results support a link between liver cell apoptosis and the miR-34a/SIRT1/p66shc pathway, which can be modulated by CA in NAFLD.
format Online
Article
Text
id pubmed-4650741
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46507412015-12-02 Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease Shan, W Gao, L Zeng, W Hu, Y Wang, G Li, M Zhou, J Ma, X Tian, X Yao, J Cell Death Dis Original Article Recent studies have demonstrated that miR-34a expression is significantly upregulated and associated with apoptosis in nonalcoholic fatty liver disease (NAFLD). Carnosic acid (CA) is a novel antioxidant and a potential inhibitor of apoptosis in organ injury, including liver injury. This study aimed to investigate the signaling mechanisms underlying miR-34a expression and the antiapoptotic effect of CA in NAFLD. CA treatment significantly reduced the high-fat diet (HFD)-induced elevations in aminotransferase activity as well as in serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and malondialdehyde (MDA) levels but increased serum high-density lipoprotein cholesterol (HDL-C) and hepatic superoxide dismutase (SOD) levels. Moreover, CA treatment ameliorated the increase in cleaved caspase-3 caused by HFD exposure and completely reversed the HFD-induced decreases in manganese superoxide dismutase (MnSOD) and B-cell lymphoma-extra large expression. CA also counteracted the HFD- or palmitic acid (PA)-induced increases in caspase-3 and caspase-9 activity. Mechanistically, CA reversed the HFD- or PA-induced upregulation of miR-34a, which is the best-characterized regulator of SIRT1. Importantly, the decrease in miR-34a expression was closely associated with the activation of the SIRT1/p66shc pathway, which attenuates hepatocyte apoptosis in liver ischemia/reperfusion injury. A dual luciferase assay in L02 cells validated the modulation of SIRT1 by CA, which occurs at least partly via miR-34a. In addition, miR-34a overexpression was significantly counteracted by CA, which prevented the miR-34a-dependent repression of the SIRT1/p66shc pathway and apoptosis. Collectively, our results support a link between liver cell apoptosis and the miR-34a/SIRT1/p66shc pathway, which can be modulated by CA in NAFLD. Nature Publishing Group 2015-07 2015-07-23 /pmc/articles/PMC4650741/ /pubmed/26203862 http://dx.doi.org/10.1038/cddis.2015.196 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Article
Shan, W
Gao, L
Zeng, W
Hu, Y
Wang, G
Li, M
Zhou, J
Ma, X
Tian, X
Yao, J
Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease
title Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease
title_full Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease
title_fullStr Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease
title_full_unstemmed Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease
title_short Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease
title_sort activation of the sirt1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of mir-34a protects rats against nonalcoholic fatty liver disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650741/
https://www.ncbi.nlm.nih.gov/pubmed/26203862
http://dx.doi.org/10.1038/cddis.2015.196
work_keys_str_mv AT shanw activationofthesirt1p66shcantiapoptosispathwayviacarnosicacidinducedinhibitionofmir34aprotectsratsagainstnonalcoholicfattyliverdisease
AT gaol activationofthesirt1p66shcantiapoptosispathwayviacarnosicacidinducedinhibitionofmir34aprotectsratsagainstnonalcoholicfattyliverdisease
AT zengw activationofthesirt1p66shcantiapoptosispathwayviacarnosicacidinducedinhibitionofmir34aprotectsratsagainstnonalcoholicfattyliverdisease
AT huy activationofthesirt1p66shcantiapoptosispathwayviacarnosicacidinducedinhibitionofmir34aprotectsratsagainstnonalcoholicfattyliverdisease
AT wangg activationofthesirt1p66shcantiapoptosispathwayviacarnosicacidinducedinhibitionofmir34aprotectsratsagainstnonalcoholicfattyliverdisease
AT lim activationofthesirt1p66shcantiapoptosispathwayviacarnosicacidinducedinhibitionofmir34aprotectsratsagainstnonalcoholicfattyliverdisease
AT zhouj activationofthesirt1p66shcantiapoptosispathwayviacarnosicacidinducedinhibitionofmir34aprotectsratsagainstnonalcoholicfattyliverdisease
AT max activationofthesirt1p66shcantiapoptosispathwayviacarnosicacidinducedinhibitionofmir34aprotectsratsagainstnonalcoholicfattyliverdisease
AT tianx activationofthesirt1p66shcantiapoptosispathwayviacarnosicacidinducedinhibitionofmir34aprotectsratsagainstnonalcoholicfattyliverdisease
AT yaoj activationofthesirt1p66shcantiapoptosispathwayviacarnosicacidinducedinhibitionofmir34aprotectsratsagainstnonalcoholicfattyliverdisease